immunotherapy

Nature Communications, Published online: 17 June 2026; doi:10.1038/s41467-026-74570-3 Therapeutic options for patients with treatment-refractory metastatic urothelial carcinoma (mUC) are much needed. Here, the authors report the outcomes and translational analysis of the phase I/II ICRA trial evaluating whether paclitaxel plus tremelimumab (anti-CTLA-4) with or without durvalumab (anti-PD-L1) ind…

This tip sheet from Sylvester Comprehensive Cancer Center, at the University of Miami Miller School of Medicine, features several cancer-related story ideas including paradoxical mesothelioma findings, a new immunotherapy drug for relapsed multiple myeloma, how gliomas evolve after treatment and more.

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

Modern cancer treatment has entered a new era thanks to immunotherapy. Instead of directly attacking cancer cells with chemicals or radiation, immunotherapy encourages the immune system to do the job itself. This approach has helped many patients live longer and has changed the outlook for several types of cancer. One of the most widely used […] The post Scientists Find a Smarter Way to Track Can…

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer…

Nature Communications, Published online: 25 May 2026; doi:10.1038/s41467-026-73562-7 While first-line immunochemotherapy has shown efficacy in patients with extensive-stage small-cell lung cancer (ES-SCLC), survival benefit is limited. Here, the authors report a phase II randomised clinical trial comparing durvalumab (anti-PD-1) plus anlotinib (multi-TKI) against durvalumab alone as maintenance t…

A drug that millions of people already use for asthma and allergies may one day become part of cancer treatment, according to a new study from Northwestern Medicine. Researchers discovered that medications blocking a molecule called CysLTR1 may help the immune system fight aggressive cancers that often resist modern immunotherapy treatments. The findings were published […] The post Asthma drug co…

Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy can improve results when added to radiotherapy-based treatment regimen for men with aggressive prostate cancer. The work, led by Kosj Yamoah, MD, Ph.D., chair of the Radiation Oncology Department at Moffitt, was published in the Journal for ImmunoTherapy of Cancer.

Nature Communications, Published online: 08 May 2026; doi:10.1038/s41467-026-72242-w CheckMate 650 was a multicohort phase 2 trial designed to study the safety and clinical activity of nivolumab plus ipilimumab combination therapy in patients with metastatic castration-resistant prostate cancer. Here the authors report the results of the randomized portion of the trial, including three different …

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have identified a promising new strategy to overcome resistance to immunotherapy in colorectal cancer, one of the leading causes of cancer-related deaths worldwide.

Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this immunotherapy in this patient group, led by UCL and UCLH researchers.

A short burst of immunotherapy before surgery is delivering surprisingly powerful results for a specific type of colorectal cancer. Patients in a UK-led trial who received just nine weeks of pembrolizumab prior to surgery have remained cancer-free nearly three years later—an outcome that challenges the standard approach of surgery followed by months of chemotherapy.

Nature, Published online: 29 April 2026; doi:10.1038/d41586-026-01193-5 In people with advanced skin cancer, injecting low doses of an anticancer immunotherapy directly into tumours, rather than administering high doses intravenously, reduced severe immune toxicity while preserving antitumour efficacy. Pre-existing antitumour immunity predicted clinical benefit most strongly, and profiling fresh …

A new UCLA Health Jonsson Comprehensive Cancer Center study suggests that the way immune cells are organized inside melanoma tumors may help researchers better understand which patients will benefit from combination immunotherapy after standard anti-PD-1 treatment stops working - and which may not.

Here’s something that sounds too simple to be true: giving cancer patients their immunotherapy before 3 PM instead of after might significantly extend their lives. No new drugs, no experimental procedures, just a shift in the appointment schedule. Yet a new study on extensive-stage small cell lung cancer, one of the deadliest cancers we know, suggests this timing tweak isn’t just helpful. It’s po…

Recognized for her innovative work on treatment-resistant and rare melanomas, Dr. Najjar will use the award to develop next-generation immunotherapy strategies.